The chromosomal translocation t(8;21) fuses the AML1 (RUNX1) gene on chromosome 21 and the ETO gene on chromosome 8 in human acute myeloid leukemias (AMLs), resulting in expression of the chimeric transcription factor AML1/ETO. AML1/ETO-mediated dysregulation of target genes critical for hematopoietic differentiation and proliferation is thought to contribute to the leukemic phenotype. Several mechanisms, including recruitment of histone deacetylases (HDACs) to AML1 target genes, may be responsible for altered gene expression. We used an ecdysone-inducible expression system in the human monoblastic U-937 cell line to isolate genes that were differentially expressed upon induction of AML1/ETO expression. By representational difference analysis (cDNA-RDA), we identified 26 genes whose expression levels were significantly modulated following AML1/ETO induction for 48 h. None of these genes has previously been described as a target of AML1, ETO or AML1/ETO. One gene downregulated by AML1/ETO in vitro, Williams Beuren syndrome critical region 5 (WBSCR5), was expressed in primary t(8;21)-negative AML blasts but not in primary t(8;21)-positive AML blasts, strongly implying a role of this gene in the phenotype of t(8;21)-positive AML. Four upregulated and four downregulated genes were further studied with all-trans-retinoic acid (ATRA), an inducer of differentiation of U-937 cells, and Trichostatin A (TSA), an HDAC inhibitor. Three out of eight genes including WBSCR5 were regulated during ATRA-induced monocytic differentiation of U-937 cells, however, none of them antagonistically, upon both ATRA treatment and AML1/ETO induction. AML1/ETO-associated dysregulation of gene expression was not mediated by a TSA-sensitive mechanism. The identified genes provide a useful model to study the mechanism by which the AML1/ETO fusion protein exerts its function in transcriptional dysregulation in AML. The possible role of WBSCR5 in normal and malignant hematopoiesis warrants further study.
Introduction
The translocation (8;21) is the most frequent chromosomal abnormality found in human acute myeloid leukemia (AML) of the subtype M2. Fusion of the AML1 gene on chromosome 21 and the ETO gene on chromosome 8 results in expression of the AML1/ETO chimeric transcription factor (Erickson et al., 1992; Miyoshi et al., 1993) . The AML1/RUNX1 gene (acute myeloid leukemia gene 1/runt-related gene 1) belongs to the small transcription factor family of the core binding factors (CBFs, also known as polyoma enhancer binding protein, PEBP2) (Kagoshima et al., 1993) . It encodes the DNA-binding a-subunit, which heterodimerizes with CBFb (Ogawa et al., 1993; Wang et al., 1993) . AML1 has been shown to act as a transcriptional activator for a number of hematopoietic specific genes, including the macrophage and granulocyte colony stimulating factor receptors (M-CSF-R and G-CSF-R), interleukin 3 (IL-3), neutrophil elastase (NE), myeloperoxidase (MPO) and macrophage/granulocyte colony stimulation factor (GM-CSF) (Nuchprayoon et al., 1994; Frank et al., 1995; Takahashi et al., 1995; Rhoades et al., 1996; Zhang et al., 1996; Britos-Bray and Friedman, 1997; Uchida et al., 1997; Shimizu et al., 2000) . However, the protein contains three repression domains and can also repress transcription, as has been reported for the p21 waf1/Cip1 promoter . Furthermore, AML1 can interact with other lineage-restricted transcription factors such as C/EBP, Ets and Myb (Giese et al., 1995; Hernandez-Munain and Krangel, 1995; Sun et al., 1995; Zaiman and Lenz, 1996; Zhang et al., 1996; Britos-Bray and Friedman, 1997; Petrovick et al., 1998; Westendorf et al., 1998) . It has been hypothesized that AML1 normally stimulates transcription by interacting with coactivators such as p300/CBP, but can be converted into a repressor through the interaction with corepressors like mSin3 or TLE/Groucho proteins (Aronson et al., 1997; Kitabayashi et al., 1998b; Levanon et al., 1998; .
The biological function of ETO, the mammalian homolog of the Drosophila protein nervy, in hematopoiesis is unknown, but has been reported to play an important role in development of the gut (Calabi et al., 2001) . It has previously been shown that ETO interacts with the nuclear receptor corepressors Sin3A/N-CoR and histone deacetylases (HDACs) (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998; Amann et al., 2001) . Therefore, by interacting with promoterbound transcription activating factors, ETO may recruit HDACs to their target promoters, resulting in repression of transcription. On the other hand, if ETO competes with other transcription factors for corepressor complex binding, transcriptional activation might be the consequence (Downing, 1999) .
A critical aim in understanding the mechanism by which AML1/ETO executes its role in malignant transformation is the identification of downstream target genes whose altered expression causes a malfunction of hematopoietic processes. The fusion protein retains some of the AML1 protein domains including the runt domain and all of the ETO protein domains. Therefore, it was hypothesized that AML1/ETO recruits corepressors and HDACs to AML1 target genes, thereby leading to repression of transcription (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998) . A transdominant negative inhibition of AML1 function has also been reported (Frank et al., 1995; Meyers et al., 1995) . However, because both wild-type AML1 and wild-type ETO can act as activators or repressors of transcription, and these functions might be disrupted by the fusion of the two proteins, it remains possible that AML1/ETO might also activate and/or repress transcription. In fact it has been shown that AML1/ETO activates the ubiquitin-specific protease UBP43, the bcl-2 promoter and synergizes with AML1 to activate the M-CSF-R promoter, and also interferes with AML1-mediated transactivation to represses transcription from the GM-CSF promoter, the NP-3 promoter and the IL-3 promoter (Frank et al., 1995; Takahashi et al., 1995; Klampfer et al., 1996; Rhoades et al., 1996; Uchida et al., 1997; Westendorf et al., 1998; Liu et al., 1999) . By differential display, Shimada et al. (2000) have identified 19 upregulated and five downregulated genes following ectopic AML1/ETO expression in the murine myeloid precursor cell line L-G. AML1/ETO has been shown to block granulocytic differentiation of 32D cells and U-937 cells (Ahn et al., 1998; Westendorf et al., 1998; Burel et al., 2001) . However, ectopic expression of the fusion protein in human monoblastic U-937 cells, murine erythroleukemia (MEL) cells as well as in a murine myeloid progenitor cell line (32D.3) interferes with cellular growth, causes disruption of the cell cycle in G1 phase and induces apoptosis (Amann et al., 2001; Burel et al., 2001) . These findings suggest that components of a yet to be identified signaling cascade normally activated by AML1/ETO in these cells might be disrupted in t(8;21)-positive blasts, which otherwise might also undergo programmed cell death. Consistent with this view is the finding that AML1/ETO alone was not sufficient, but cooperated with other genetic mutations, to cause leukemic transformation in transgenic mouse models (Rhoades et al., 2000; Downing, 2001; Yuan et al., 2001) .
In this study, we used an ecdysone-inducible AML1/ ETO expression model in U-937 cells to identify genes under downstream control of the chimeric transcription factor by representational difference analysis (RDA). Of 26 genes, preliminarily classified as differentially expressed and thus far not described to be regulated by AML1, AML1/ETO or ETO, eight were further analysed. One of the genes, WBSCR5, was also repressed in primary t(8;21)-positive AML as compared to t(8;21)-negative AML. Expression of five genes including WBSCR5 was modulated in an additive or synergistic fashion by ATRA treatment and AML1/ ETO induction, but none of them was antagonistically regulated by ATRA and AML1/ETO. The novel putative target genes were not regulated by AML1/ ETO via a Trichostatin A (TSA)-sensitive mechanism, pointing to a mechanism not involving HDACs. The identification of target genes affected by the chimeric transcription factor may help to understand the dual function of growth inhibition versus transformation, and may contribute to clarify the mechanism by which AML1/ETO interferes with transcriptional regulation.
Results
Differential gene expression in AML1/ETO-positive and -negative U-937 cells: RDA To study the effect of prolonged AML1/ETO expression, comparable to the in vivo situation of t(8;21)-positive leukemic cells, we employed the ecdysoneinducible two-vector system to conditionally express the AML1/ETO fusion protein in human monoblastic U-937 cells. A heterodimeric hormone receptor encoded by pVgRXR is constitutively expressed and becomes activated through binding of its ligand (Ponasterone A, a synthetic ecdysone derivative). The activated receptor binds to response elements in the promoter region provided by the second vector pIND-AML1/ETO, thereby transcriptionally activating the expression of the transgene. Single U-937 cell clones were selected after cotransfection and analysed for AML1/ETO protein expression upon hormone treatment (Fliegauf et al., 2003) . However, AML1/ETO was recently shown to induce growth arrest and apoptosis upon prolonged expression . One clone (named 9/14/18) was identified, which was tightly controlled (and therefore not preselected for tolerable AML1/ETO expression) and reliably showed highlevel AML1/ETO protein expression following addition of hormone. In this clone, AML1/ETO induction for 24 h only moderately changed cell viability but caused an average decrease in viability of 11% after 48 h (five independent experiments) and 14% after 72 h (10 independent experiments), respectively (data not shown). In order to study differential gene expression, a Novel AML1/ETO target genes M Fliegauf et al 48-h hormone treatment of this clone with 5 mM Ponasterone A therefore appeared as a reasonable compromise between strong AML1/ETO expression (protein levels comparable to Kasumi-1 cells) and the first onset of an overall change of cellular growth and viability.
RDA was performed in both directions, with AML1/ ETO-expressing cells as the tester population and nonexpressing cells as the driver population, and vice versa, to identify genes that were upregulated and those that were downregulated upon AML1/ETO expression, respectively. The size distribution of the initially amplified complex cDNA mixtures (the so-called 'Representations') varied substantially upon modifications of the PCR conditions (Figure 1 ; see Materials and methods for details) and it was assumed that different cDNA species were preferentially amplified under these variable conditions. Therefore, two PCR systems (denominated HS and E) were used for each forward and reverse RDA. Thus four RDA reactions with three rounds each were performed in parallel with identical cDNA sources. As an internal positive control, enrichment of AML1/ETO-specific cDNA fragments in the forward reactions as well as its elimination in the reverse subtractions was confirmed by Southern blot hybridization (Fliegauf et al., 2003 and data not shown).
A total of 68 RDA 'bands' were isolated from the second and third round difference products (DPs). The most prominent 28 bands were used as radiolabeled probes and hybridized to Representation blots (containing the unsubtracted cDNA fragments that were used as the RDA starting material) and Northern blots (data not shown), to control for homogeneity of the bands, and to test whether they contain 'true differences' (Hubank and Schatz, 1999) . The cDNA fragments derived from 27 bands were subcloned and approximately 400 individual RDA clones were subsequently analysed by sequencing and BLAST search. Among them, 127 different clones were identified with variable abundance. Importantly, none of the cDNA fragments derived from the HS reactions were obtained by the E reactions and vice versa (Table 1) . Furthermore, none of the previously reported AML1/ETO target genes were identified in this study, except the human homolog of the rat b-galactoside-a2,6-sialyltransferase (Shimada et al., 2000) whose differential expression could not be verified in our system (data not shown).
Multiple genes are regulated by forced AML1/ETO expression
Highly abundant RDA clones and cDNA fragments corresponding to genes associated with cellular growth Figure 1 Screening of the RDA-generated cDNA fragments for differential expression of the corresponding endogenous genes revealed a good correlation between Representation blots (panel a) and Northern blots (panels b, c). Cells were treated with ethanol (À) or 5mM Ponasterone A ( þ ) for 48 h as indicated. Several identical blots were prepared and repeatedly hybridized using the RDA-generated cDNA fragments as radiolabeled probes. AML1/ ETO expression was confirmed by hybridization using a probe derived from the AML1/ETO cDNA. GAPDH hybridizations and ethidium bromide staining of the gels are shown to confirm equal loading. The cDNA fragment that could be readily detected in the unsubtracted RDA HS-PCR reactions by an RT-PCR-generated GAPDH probe was not or only weakly amplified in the RDA E reactions. Constitutive expression of the VgEcR subunit of the heterodimeric ecdysone receptor (the RXR subunit is not shown) in clones 9/14/18 and 9/11/1 and the inducible LacZ expression in clone 9/11/1 were confirmed using probes derived from the respective expression vectors. Shown are seven (out of 70) hybridizations, as indicated. (a) Unsubtracted RDA starting material (the amplified ds-cDNA fragments prepared from clone 9/14/18 after a 48 h hormone treatment, following ligation of the first adapters and amplification with the two different PCR systems, HS and E) was used for the Representation blots. (b) Northern blots were prepared from clone 9/14/18, which was induced to express the AML1/ETO fusion protein for 48 h (this induction was independent of the RDA experiment), and expression levels were compared to wild-type U-937 cells in the presence and absence of the inducer to control for hormone effects. (c) An AML1/ETO low-expressing clone (7/15/7) and a LacZ control clone (9/11/1), which inducibly expresses the bacterial b-galactosidase instead of AML1/ETO, were used as controls for hormone and hormone receptor effects, respectively. Not shown are a number of other controls that have been included in the screening procedure: clone 9/14/18 was independently treated with hormone for 24/30/48 and 72 h, to confirm that the expression differences were not unique to a single AML1/ETO induction experiment and wild type U-937 were compared to the t(8;21)-positive cell line Kasumi-1 Novel AML1/ETO target genes M Fliegauf et al and survival were selected for further verification of differential expression. In addition, numerous lowabundant clones or unknown sequences were chosen at random. In total, 70 different RDA-derived cDNA fragments were used as radiolabeled probes and hybridized to Representation blots (containing the unsubtracted RDA starting material) and Northern blots. A highly sensitive Representation blot (Figures 1a and 2) was included, because the cDNA fragments were relatively short and at least some of them could not be labeled to high specific activity or did not hybridize well under standard conditions. For the analysis of differential expression by Northern blot hybridization, clone 9/14/18 was treated with the hormone carrier ethanol or 5 mM Ponasterone A to induce AML1/ETO expression for 48 h ( Figure 1b) . To exclude the possibilities of hormone or hormone receptor effects, nontransfected wild-type U-937 cells (panel b), a LacZ control clone (which inducibly expresses the bacterial b-galactosidase), and a clone inducibly expressing AML1/ETO at a very low level (panel c) were used as controls. Figure 1 shows two genes whose expression was 'switched on' (CYP1A1 and CA6) or strongly induced (P2X4), as well as four genes that were repressed to variable degrees upon conditional AML1/ETO expression in U-937 cells (HS3ST2, HOXA10, HSPCO70 and WBSCR5). Similar expression levels of the hormone receptor subunits, and control hybridizations in weakly AML1/ETO-expressing clone 7/15/7 and LacZ-expressing clone 9/11/1 show that differential expression of the above genes in clone 9/14/18 was specifically dependent on AML1/ETO expression. The results obtained from Northern blot hybridization (Figure 1b and c) correlated well with those from the Representation blots ( Figure 1a) . Therefore, the Representation blots (similar approaches are sometimes also referred to as 'reverse Northern blots') were considered to reliably display the mRNA expression pattern and were used to select individual RDA clones for further analysis (Figure 2 ), even where Northern blot hybridizations failed to produce detectable signals. Among the 70 different RDA clones tested, a total of 13 genes were upregulated and 13 downregulated significantly upon AML1/ETO expression in U-937 cells (Table 1) . Both PCR systems (HS and E) resulted in identification of an equal number of candidate genes and therefore performed equally well. Table 1 summarizes all 26 potential AML1/ETO target genes identified by this approach. However, it should be (Figure 3 ) with wild-type U-937 cells as negative and Kasumi-1 cells as positive controls, respectively. The lysozyme gene, identified to be repressed by AML1/ETO in U-937 cells by an RDAindependent approach, was also included (Fliegauf et al., 2003) . The CYP1A1 gene encodes a cytochrome P450 monooxygenase involved in detoxification of lipophilic substrates like steroid hormones (Whitlock, 1999) , suggesting a nonspecific cellular response to contact with Ponasterone A. However, expression of this gene was only induced upon AML1/ETO expression in transfected U-937 cells, but not by Ponasterone A in wild-type U-937 cells. Three of the four genes that were activated by AML1/ETO in U-937 cells were not expressed by Kasumi-1 cells (CYP1A1, CA6 and EBI3). On the other hand, the downregulated genes HS3ST2, HOXA10 and WBSCR5 were undetectable in Kasumi-1 cells, and NEK-6 was expressed at lower levels in Kasumi-1 compared to U-937, indicating that repression was not a unique feature of our inducible U-937 model. Following the verification of the differential expression of the potential AML1/ETO target genes in our U-937-AML1/ETO cell line model, and the concordant reduced expression of four of these genes in Kasumi-1 cells in vitro, expression in primary acute leukemias in vivo was examined as a next level of validation. Therefore, AML blasts from three patients with a Figure 2 Differentially expressed genes identified by Representation blot hybridization. As shown in Figure 1 , signals obtained from the more sensitive Representation blots correlated well with those from Northern blots. The RDA-generated cDNA fragments that were used as radiolabeled probes were relatively short (down to 200 bp) and, therefore, some of them might not have been suitable for Northern blot hybridization (indicated by asterisks), whereas almost all probes gave detectable signals on Representation blots (containing the unsubtracted RDA starting material). Square brackets indicate RDA clones that contain more than one cDNA fragment. Shown are 10 candidate genes that appeared to be upregulated upon AML1/ETO expression in U-937 cells (left panel) and eight genes whose expression appeared to be repressed (right panel). An unchanged control (negative clone) is shown on the right side below. The Representation blots are identical to those shown in Figure 1a . HS and E are the two PCR systems used to amplify the dscDNA fragments derived from U-937 cells (clone 9/14/18) in the absence (À) and presence ( þ ) of AML1/ETO for 48 h (see Figure 1 for ethidium bromide, GAPDH and AML1/ETO controls) (Figure 4b) .
A time-course experiment shows that repression of WBSCR5 mRNA is readily detectable 10 h after induction of AML1/ETO in U-937 cells (Figure 4c ). Together, these results strongly suggest WBSCR5 being under transcriptional control of AML1/ETO, both in vitro and in vivo.
Cooperative effects of AML1/ETO and all-trans-retinoic acid on regulation of WBSCR5 and other putative target genes during myeloid differentiation AML1/ETO expression has been shown to block differentiation of myeloid progenitor cells (Ahn et al., 1998; Kitabayashi et al., 1998a; Westendorf et al., 1998; Hwang et al., 1999; Kohzaki et al., 1999) . Thus, the effect on differentially expressed genes might represent interference with the differentiation program of U-937 cells. We therefore asked whether expression of the identified genes is also modulated upon ATRA-induced granulocytic differentiation of U-937 cells, and whether these genes are antagonistically regulated by ATRA and AML1/ETO. Five of eight genes (P2X4, HS3ST2, HOXA10, NEK-6 and WBSCR5) were expressed to a variable degree in wild-type U-937 cells. After treatment with 1 mM ATRA for 24 h, expression levels of P2X4, HOXA10, NEK-6 and WBSCR5 remained unchanged, while HS3ST2 expression was decreased (Figure 3) . Among the three genes not expressed (at least at levels detectable with the cDNA probes used), CYP1A1, CA6 and EBI3, only CA6 was slightly induced by ATRA in wild-type U-937 cells. Thus two of eight genes (CA6 and HS3ST2) were regulated during ATRA-induced myeloid differentiation of U-937 cells. ATRA enhanced the repressive effect of AML1/ETO on HS3ST2 expression, but did not alter the effect of AML1/ETO on CA6 expression. Interestingly, among the genes not regulated by ATRA in wild-type U-937 Figure 3 Potential AML1/ETO target genes and their regulation during ATRA-induced differentiation of U-937 cells. Clone 9/14/18 and wild-type U-937 cells were treated with ethanol (ÀPonA) or 5 mM Ponasterone A ( þ PonA) for 24 h prior to the addition of the ATRA carrier ethanol (ÀATRA) or 1 mM ATRA ( þ ATRA) for further 24 h. Several identical Northern blots were prepared for each panel. The 28S and 18S rRNAs are indicated on the right side. AML1/ETO expression was confirmed by Northern blot hybridization (top) and Western blot (bottom). Note that ATRA enhances AML1/ETO mRNA expression. GAPDH control hybridization and ethidium bromide staining of the gels show equal loading. cDNA fragments generated by RDA were used as radiolabeled probes as indicated. The lysozyme gene, which contains five perfect matches of the TGT/cGGT AML1 consensus binding site (Meyers et al., 1993) in a 2.2 kb promoter upstream region (Riccio and Rossolini, 1993) , was found to be repressed upon AML1/ ETO expression in U-937 cells by an RDA-independent approach. Shown below is the constitutive expression of the heterodimeric ecdysone receptor (subunits RXR and VgECR) in the stably transfected clone 9/14/18 Novel AML1/ETO target genes M Fliegauf et al cells (CYP1A1, P2X4, EBI3, HOXA10, NEK-6 and WBSCR5), combined AML1/ETO induction and ATRA treatment resulted in an enhanced effect of AML1/ETO on activation of CYP1A1 (synergistic) and EBI3 and augmented AML1/ETO-related repression of NEK-6 and WBSCR5. However, induction of AML1/ETO mRNA expression was also slightly enhanced by ATRA. In summary, the effects of AML1/ ETO on expression of putative target genes were enhanced by ATRA in five out of eight genes, including WBSCR5.
The HDAC inhibitor TSA enhances AML1/ETO-induced modulation of target gene expression AML1/ETO is thought to act as a transcriptional repressor for target genes of wild-type AML1 and possibly other sequence-specific transcription factors that interact with AML1/ETO. This feature has been attributed to the recruitment of nuclear corepressors and HDACs, mediated by the ETO moiety of the fusion protein (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998; Amann et al., 2001) . We tested this hypothesis for the eight selected genes, by preincubation with the HDAC inhibitor TSA for 24 h prior to AML1/ ETO induction for another 24 h (Figure 4 ). In our hands, even moderate doses of TSA (100-200 nM) caused pleiotropic side effects (including transgene activation) in our AML1/ETO expression model (data not shown), which could be diminished by preincubation of the cells with a low TSA concentration (50 nM) prior to AML1/ETO induction. TSA alone did not affect expression of any of the tested genes except P2X4 in wild-type U-937 cells, and only slightly induced the basal expression of CA6, EBI3, and lysozyme in the noninduced U-937-AML1/ETO cells. AML1/ETO-dependent induction of four genes (CYP1A1, CA6, P2X4 and EBI3) was significantly enhanced by TSA pretreatment. This effect was dramatic for CA6, and 2-4-fold for the other three genes. Among the four genes downregulated by AML1/ETO, repression was enhanced for HS3ST2, NEK-6 and WBSCR5 but remained unaffected for HOXA10. In conclusion, TSA did not antagonize the effect of AML1/ETO on expression of the genes analysed in this study.
Discussion
Expression of the chimeric transcription factor AML1/ ETO is a consistent feature of the leukemic blasts in t(8;21) AML (Nucifora and Rowley, 1995) . The chromosomal translocation results in the fusion of parts of the AML1 and ETO proteins. This chimeric transcription factor leads to an altered transcriptional control that might ultimately result in perturbation of blood cell differentiation (Downing, 1999; . Thus far, a number of AML1 and/or AML1/ETO target genes have been identified, but it remains unclear whether dysregulation of these genes is directly causative for leukemogenesis.
We established an ecdysone-inducible AML1/ETO expression system in human monoblastic U-937 cells. Conditional AML1/ETO expression in U-937 cells for more than 48 h markedly impaired cellular growth and committed the cells to undergo apoptosis (data not shown), which has also been observed by others ).
In order to identify downstream targets of the leukemia-specific transcription factor in U-937 cells, cDNA-RDA was performed in both directions (forward and reverse), revealing a preliminary number of 26 putative novel AML1/ETO target genes. Interestingly, none of the newly identified genes has previously been described as an AML1 or AML1/ETO target. It may be concluded that the total number of genes under downstream control of AML1/ETO may be considerably high. Likewise, the different approaches for target gene identification and the specific cellular backgrounds as well as differences introduced by the use of heterologous systems or studies in other species may contribute to this variability.
With several independent AML1/ETO induction experiments including various controls, we could almost fully exclude artificial effects on the identified differentially expressed genes which therefore must be assumed as true differences in this particular cell culture system. Possibly due to the limited number of AML blood samples that could have been included in this work, most of the observed in vitro effects remained undetectable in vivo. In fact, preliminary data from microarray experiments using a large number of individual blood or bone marrow samples from patients with AML-M2 either with t(8;21) or normal karyotype indicate a considerable variability of the expression levels of several potential target genes described here (T Haferlach, personal communication). These results underline the usefulness, but also the limitations, of such in vitro models.
We showed that WBSCR5 expression is not only downregulated by forced AML1/ETO expression in U-937 but is also repressed in Kasumi-1 cells, in SKNO1 cells (data not shown), as well as in primary AML1/ETO-positive AMLs carrying t(8;21) as compared to AML without t(8;21) or normal bone marrow. This strongly indicates a functional relevance of this regulation in vivo. WBSCR5 comprises 11 exons and encodes a 243 aa protein. The gene is located on chromosome 7 within segment q11.23, a region that is deleted in the human autosomal dominant disorder Williams-Beuren syndrome (WBS, OMIM 194050) . WBS is characterized by a number of symptoms including vascular, neurological, behavioral and skeletal abnormalities, including dental malformation (Grimm and Wesselhoeft, 1980; Francke, 1999) . The WBSCR5 expression pattern comprises, among other organs, peripheral blood cells (Doyle et al., 2000) . So far the physiological function of WBSCR5 has not been well examined.
Recently, a function for WBSCR5, which is also termed NTAL/LAB (non-T-cell activation linker/linker for activation of B cells), in the activation and differentiation of B cells as well as mast cell degranulation has been reported (Brdicka et al., 2002; Janssen et al., 2003; Koonpaew et al., 2004; Tkaczyk et al., 2004) . NTAL/LAB was found to be expressed in B cells, NK cells, monocytes and mast cells, and represents a 25-30 kDa phosphoprotein, with a 6 aa N-terminal extracellular peptide, a single putative hydrophobic trans-membrane domain and a cytoplasmic signaling domain composed of nine tyrosine residues. Upon phosphorylation, the adaptor protein participates in signaling cascades leading to the described cellular responses. However, the role of WBSCR5 in leukemogenesis is as yet unclear.
Taken together, the results presented here indicate that ectopic expression of AML1/ETO in U-937 cells predominantly interferes with general cellular homeostasis. Since a feed-forward signaling cascade initiated by the fusion protein might also cause these effects, the 'true direct targets' might not have been detected by RDA. Sequence scanning of the 5 0 upstream regions of WBSCR5 and several others of the newly identified genes for AML1 consensus binding sites, without functional analyses, did not give clear indication to primary targets (data not shown). However, direct transcriptional regulation might only be one function of the fusion protein, which has also been proposed to act in a more complex manner most likely by protein-protein interaction (Petrovick et al., 1998; Mao et al., 1999; Shimada et al., 2000; Shimizu et al., 2000) . This might be of particular importance considering that t(8;21)-positive AML blasts are influenced by prolonged AML1/ETO expression. In this view, forced AML1/ETO expression for 48 h is more closely related to the in vivo situation than a short-term induction or even transient expression.
Ectopic AML1/ETO expression has been shown to block cytokine-induced differentiation of murine 32D and LG cells (Ahn et al., 1998; Kitabayashi et al., 1998b; Westendorf et al., 1998; Hwang et al., 1999; Kohzaki et al., 1999) . In addition, inactivation of AML1/ETO in t(8;21)-positive Kasumi-1 and/or SKNO-1 cells by antisense oligonucleotides or ribozyme approaches has been shown to block proliferation and to induce differentiation and apoptosis, respectively (Sakakura et al., 1994; Matsushita et al., 1995; Kozu et al., 1996; Heidenreich et al., 2003) . We determined whether the newly identified putative AML1/ETO target genes are also regulated during ATRA-induced monocytic differentiation of U-937 cells. Out of the eight genes tested, three were concordantly regulated upon ATRA treatment and AML1/ETO induction. Surprisingly, none of the investigated genes was regulated in a contrary fashion. This would have been expected if the identified AML1/ETO-regulated genes were involved in myeloid differentiation, which was blocked by AML1/ETO but promoted by ATRA in this cellular system. Thus, it appears unlikely that AML1/ETO-mediated dysregulation of WBSCR5 or the other genes contributes to the block of differentiation observed with other cell line models.
Irrespective of a direct or indirect AML1/ETOassociated effect on alteration of gene expression, it should be possible to inhibit or to attenuate these activities by blocking AML1/ETO function. AML1/ ETO is thought to interact via the ETO moieties with nuclear corepressor complexes and HDACs. Our results using TSA to inhibit HDAC activity showed no antagonistic effect on AML1/ETO-mediated gene regulation. Since AML1/ETO-associated regulation of these genes was not mediated by a TSA-sensitive mechanism, these results argue against the hypothesis that the fusion protein exclusively acts via HDAC recruitment. However, it should be noted that our ecdysone-inducible model has the limitation that TSA moderately enhances transgene expression. Therefore, results from expression analysis in the absence and presence of hormone and TSA, respectively, should be analysed carefully.
In conclusion, this work provides a set of novel AML1/ETO-regulated genes that might have implications in leukemogenesis and gives new evidence that AML1/ETO-dependent gene repression is not exclusively mediated by recruitment of HDACs.
Materials and methods

Cell culture
Human myeloid U-937 and Kasumi-1 cells (German Collection of Microorganisms and Cell Cultures, DSMZ, Braunschweig, Germany) were cultured in RPMI 1640, supplemented with 10% (U-937) or 15% (Kasumi-1) fetal calf serum, 2-4 mM L-glutamine, 1 mM sodium pyruvate and 100 U/ml penicillin/ streptomycin (all from Gibco, Karlsruhe, Germany) at 371C and 5% CO 2 . Individual U-937 cell clones, stably cotransfected with an ecdysone-inducible AML1/ETO expression system (Invitrogen, Groningen, The Netherlands; No et al., 1996) , were maintained in the presence of 600 mg/ml G418 (Gibco) and 150 mg/ml Zeocin (Invitrogen). AML1/ ETO expression was induced by adding 5 mM Ponasterone A (Invitrogen) directly to the cell cultures. The noninduced controls were treated with the same amount of the carrier ethanol.
For measurements of the apoptosis rate, cells were resuspended in RPMI 1640/0.5% BSA and were mixed with an equal volume of DiOC 6 (3,3 0 dihexyloxacarbocyanine iodide)/PI staining solution (Zamzami et al., 1995 (Zamzami et al., , 1996 Burger et al., 2000) . Samples were incubated for 15 min at 371C and analysed on a Becton Dickinson FACSCalibur.
Bone marrow or peripheral blood samples from five AML patients containing 490% AML blasts (kindly provided by G Heil and J Krauter, University of Hannover, Germany) were purified by Ficoll gradient centrifugation. AML blasts were washed in phosphate-buffered saline (PBS), lysed in RNA extraction buffer (Chomczynski and Sacchi, 1987) and subjected to RNA isolation.
Southern blot
DNA was resolved on 1-2.5% agarose gels. Gels were soaked for at least 20 min in 0.25 M HCl and 1 h in 0.5 M NaOH/1.5 M NaCl and DNA was transferred onto positively charged Nylon membranes (Hybond N þ , Amersham, Freiburg, Germany) using 0.5 M NaOH/1.5 M NaCl as transfer buffer.
Northern blot
Total RNA was isolated by the acid guanidinium thiocyanate extraction method (Chomczynski and Sacchi, 1987) and resolved on 1% agarose/0.66 M formaldehyde/1 Â MOPS gels (20 Â MOPS: 400 mM MOPS, 100 mM NaAc, 20 mM EDTA, pH 7). Gels were washed for 10 min in 0.05 M NaOH/1 Â SSC, twice for 20 min with 10 Â SSC, and blotted onto Hybond N þ membranes with 10 Â SSC as transfer buffer.
Radioactive labeling and hybridization
Probes were radiolabeled using a random priming kit (Amersham). After crosslinking (Stratalinker, Stratagene, Amsterdam, The Netherlands), filters were hybridized overnight at 60-651C in Church buffer (0.5 M phosphate buffer pH 7.2, 7% (w/v) SDS, 1 mM EDTA, 100 mg/ml Salmon sperm DNA), washed twice for 5 min with 2 Â SSC/0.1% SDS and twice for 15-20 min with 0.2 Â SSC/0.1% SDS at 55-651C and exposed to XOMAT-AR X-ray films (Kodak, Stuttgart, Germany) in the presence of intensifying screens. Probes were removed with boiling 0.1-0.5% SDS prior to rehybridization of the filters.
Western blot
Cells were harvested by centrifugation, washed with PBS and lysed in Laemmli buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 2% b-mercaptoethanol, 15% glycerol, 0.1% bromophenol blue). Samples were boiled for 10 min, resolved by SDS-PAGE using a minigel apparatus (Hoefer, Amersham Pharmacia Biotech, Freiburg, Germany) and transferred to PVDF membranes (Hybond P, Amersham) using a three buffer system (A1: 300 mM Tris-HCl pH 10.4; A2: 25 mM Tris-HCl pH 10.4; K: 40 mM D,L-norleucine, 25 mM Tris-HCl pH 9.4; Kyhse-Andersen, 1984) and a semidry blotting apparatus (Hoefer) following the manufacturer's instructions. Filters were blocked with 5% skim milk (Fluka, Deisenhofen, Germany) in Tris-buffered saline/Tween 20 (TBS-T: 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween 20) for 1 h to overnight. AML1/ETO protein was detected with 2-2.5 mg/ml of an ETO-specific rabbit antibody (Oncogene Research Products, Calbiochem-Novabiochem, Bad Solden, Germany) and a 1 : 5000 diluted horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (Santa Cruz, Santa Cruz, CA, USA) using an ECL detection system (ECL-plus, Amersham) and XOMAT-AR X-ray films (Kodak). Antibodies were diluted in TBS-T/5% skim milk, and filters were incubated for at least 1 h at room temperature. Following each antibody incubation, membranes were washed twice for 5 min and twice for 20 min in TBS-T, with a final wash for 10 min with TBS prior to ECL detection. Coomassie blue staining of the gels after transfer and the membranes after ECL detection was performed, to confirm equal loading and efficient transfer.
cDNA-RDA
Poly(A) þ RNA was purified from total RNA by two passages over oligo(dT) cellulose columns (New England Biolabs, Frankfurt, Germany). Double-stranded cDNA (ds-cDNA) was synthesized following the Superscript Choice system protocol (Gibco). cDNA-RDA was performed essentially as described by Hubank and Schatz utilizing the BamHI oligonucleotide linkers Wigler, 1993, 1995; Schatz, 1994, 1999; Schutte et al., 1995) . In a parallel approach (protocol kindly provided by MA van Dijk, Utrecht University, The Netherlands), PCR conditions were slightly modified (2.5 mM MgCl 2 , 0.5 mM dNTP, final volume 100 ml instead of 4 mM MgCl 2 , 0.32 mM dNTP, final volume 200 ml). The population of preferentially amplified cDNA fragments varied substantially upon modification of PCR conditions, as indicated by the size distribution of the amplicons. RDA was performed in both directions, with noninduced U-937-AML1/ETO cells as driver and AML1/ ETO-expressing cells as tester and vice versa. First and second round hybridizations were performed with a 100 : 1 and 800 : 1 driver : tester ratio, respectively, and for the third round, 25 000 : 1 and 10 000 : 1 ratios were used (a 40 000 : 1 stringency appeared too strong). Digested DPs were purified by gel extraction (Qiagen, Hilden, Germany) prior to ligation of new oligonucleotide linkers, and successful ligation of adapters was confirmed by PCR. Second and third round RDA products were digested with DpnII; a total of 68 individual bands were isolated and purified by gel extraction and 27 of them were cloned into the BamHI site of pBluescript SKÀ (Stratagene).
Screening of RDA products
A total of 28 isolated bands from DPs 2 and 3 were used as radiolabeled probes and hybridized to Representation blots (Southern blots using the initially amplified unsubtracted cDNA fragments) and Northern blots (Hubank and Schatz, 1999) . The cloned products of 27 bands were isolated by plasmid minipreparation or colony PCR using T3 and T7 primers (von Stein et al., 1997) . Individual cDNA fragments were identified by automated sequencing (ABI 377 sequencer) and BLAST search, and were used as probes for Representation and Northern blot hybridization to confirm differential expression.
